Description: Pegozafermin, a fibroblast growth factor FGF21 analog, is an endogenous metabolic hormone that regulates energy expenditure and glucose and lipid metabolism. It reduces triglyceride (TG) levels and is used for non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG) [1] [2].